Last $123.70 USD
Change Today +0.17 / 0.14%
Volume 1.3M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 4:15 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Open
$124.16
Previous Close
$123.53
Day High
$124.31
Day Low
$122.74
52 Week High
02/27/14 - $153.10
52 Week Low
07/30/13 - $90.93
Market Cap
41.3B
Average Volume 10 Days
2.2M
EPS TTM
$-0.11
Shares Outstanding
333.6M
EX-Date
11/10/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (VRX)

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

17,200 Employees
Last Reported Date: 02/28/14
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.8M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Chief Legal Officer, Head of Corporate & Busi...
Total Annual Compensation: $750.0K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $511.1K
Consultant
Total Annual Compensation: $37.9K
Compensation as of Fiscal Year 2013.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant it has Filed a Complaint with Securities Regulators in Quebec and the U.S

Valeant said on July 21, 2014 it has filed a complaint with securities regulators in Quebec and the U.S. over allegedly unfair tactics by Allergan Inc. Valeant said it has contacted both the Autorité des marchés financiers and the U.S. Securities and Exchange Commission regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information. Valeant says Allergan falsely stated last Friday in an SEC filing that Valeant's Bausch + Lomb pharmaceutical sales were stagnant or declining, when in fact they grew about 6% in the second quarter. The U.S. prescription pharmaceutical business grew 17% over the year-earlier period, with the lion's share of that growth due to volume increases.

Galderma S.A. to Distribute Valeant Pharmaceuticals International, Inc.'s Products

Galderma S.A. announced that it has gained full rights to distribute Restylane(R), Perlane(R), Emervel(R), Sculptra(R) and Dysport(R) from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide. Galderma will pursue to distribute the acquired products through the existing distribution partner. Healthcare practitioners are invited to continue to order products through their current account number and phone numbers. Beginning July 28, 2014 Galderma will have a new branded distribution process. All accounts will automatically receive a new Galderma account number and information on the new ordering process.

Valeant Pharmaceuticals International, Inc. Receives U.S. Food and Drug Administration Clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine

Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane(R) Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Silk is a crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body. Restylane Silk is non-animal based and free from animal protein. Allergy pretesting is not necessary. Restylan Silk contains 0.3% lidocaine, which was added to reduce the discomfort associated with the treatment. Clinical study was conducted with Restylane(R) Silk to evaluate the safety and effectiveness of injections to enhance lip fullness and to improve the wrinkles around the lips. The study included 221 mostly female subjects and evaluated subjects with light and dark skin. Subjects with very dark skin were not studied. 98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection. The majority of adverse events were mild in intensity and the most common symptoms were lip swelling, contusion, and lip pain. The incidence of adverse event decreased significantly after the second treatment. Restylane Silk is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients with a history of allergies to gram positive bacterial proteins; patients with bleeding disorders; for implantation in anatomical spaces other than the dermis or submucosal implantation for lip augmentation and should not be used in patients with previous hypersensitivity to local anesthetics of the amide type, such as lidocaine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $123.70 USD +0.17

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $214.85 USD -0.09
Astellas Pharma Inc ¥1,423 JPY +8.00
Mylan Inc/PA $50.40 USD -0.13
Shire PLC 4,915 GBp -27.00
Sun Pharmaceutical Industries Ltd 789.15 INR 0.00
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 8.1x
Price/Cash Flow 89.2x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.